Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q2 2026 earnings Thursday July 30, 2026 before market open. Amvuttra (vutrisiran) quarterly revenue crossed $1 billion for the first time at $1.012 billion (approximately a $4 billion annualized run rate approximately 15 months after the ATTR-CM launch). Total Q2 revenue reached $1.29 billion (+67% year-over-year) but fell short of the $1.31 billion analyst consensus. Net product revenues were $1.17 billion (+74% YoY) versus the $1.22 billion estimate. GAAP diluted EPS was $1.21 versus the $1.49 estimate. Full-year 2026 TTR product sales guidance was revised down to $4.2-4.5 billion to reflect normalized second-line volume after the initial pent-up demand from patients waiting for a new therapy. Pipeline updates: Alnylam expects to announce clinical data from Phase 1 and Phase 2 trials of ALN-6400 in healthy volunteers and patients with hereditary hemorrhagic telangiectasia (HHT) in second-half 2026, plus results from the Phase 1 trial of ALN-2232 (Alnylam's second obesity-track siRNA) in the same second-half window. The ALN-6222 obesity siRNA Phase 1 trial (NCT07624071) opened enrollment in July 2026 with a first-in-human single-ascending-dose design in adults with BMI 30-40 kg/m² at a single site in Mount Royal, Canada through December 2027.
Sanofi (NASDAQ: SNY) reported Q2 2026 earnings Thursday July 30, 2026 with net sales of €11,597 million (+17.8% at constant exchange rates, +16.0% at actual rates) and business EPS of €2.09 (+33.3% CER), both beating consensus. Growth drivers: Dupixent (dupilumab, IL-4/IL-13 receptor blocking antibody co-marketed with Regeneron) reached Q2 sales of €5,154 million (+37.6% CER); new pharma launches reached €1,305 million (+48.3% CER). Sanofi raised full-year 2026 guidance: sales now expected to grow approximately 10% at CER, with business EPS at CER expected to grow slightly faster than sales. Three pipeline discontinuations disclosed with the earnings release: amlitelimab (OX40-ligand monoclonal antibody previously advanced in atopic dermatitis after acquisition from Kymab; the intangible asset was impaired by €952 million with an announced decision that the drug would not represent a substantial improvement to the standard of care), itepekimab (IL-33 antibody previously advanced in COPD, chronic urticaria, and other Type 2 inflammation indications), and balinatunfib. Stock reaction was mixed with Sanofi shares slipping in premarket trading on the pipeline setbacks despite the earnings beat.
Biogen (NASDAQ: BIIB) reported Q2 2026 earnings before market open Wednesday July 29, 2026 with total revenue of $2.74 billion (+3% year-over-year), GAAP diluted EPS of $0.66, and non-GAAP diluted EPS of $3.60, beating Wall Street consensus. Growth-portfolio drugs (LEQEMBI, SKYCLARYS, SYFOVRE, and EMPAVELI) delivered year-over-year growth and, in aggregate, growth-portfolio revenue exceeded $1 billion for the quarter, surpassing Biogen's legacy multiple sclerosis franchise. Two major pipeline milestones anchored the earnings call: the FDA approved LEQEMBI IQLIK (lecanemab-irmb, a subcutaneous autoinjector formulation) for at-home initiation dosing (following the earlier approval of LEQEMBI IQLIK for maintenance dosing), providing patient-friendly dosing throughout the treatment course; and the Apellis acquisition that closed May 14, 2026 contributed $128 million in combined SYFOVRE (pegcetacoplan intravitreal, for geographic atrophy) and EMPAVELI (pegcetacoplan subcutaneous, for paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy) revenue in the partial quarter. Biogen expects approximately 0.85 EPS dilution from the Apellis acquisition in 2026 with accretion in 2027 and estimated run-rate synergies of at least $250 million exiting 2027. 2026 revenue guidance raised to mid-single-digit growth with non-GAAP EPS guidance of $12-13.
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open with an 8:30 AM ET conference call. Wall Street consensus estimates: EPS of $2.05 (+540.6% year-over-year) and revenue of $1.32 billion (+70.4% year-over-year), reflecting the continued commercial ramp of Amvuttra (vutrisiran) across both hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) after the Q1 2026 Amvuttra revenue of $889.9 million (+187% YoY). Analyst focus areas beyond the base-business ramp include: the ALN-6222 first-in-human Phase 1 obesity siRNA program (NCT07624071) that opened enrollment in July 2026 as a randomized double-blind placebo-controlled single-ascending-dose study of an undisclosed-target subcutaneous siRNA in adults with BMI 30-40 kg/m²; the ALN-2232 Phase 1 obesity program (Alnylam's second obesity-track siRNA) with Phase 1 readout expected in the second half of 2026; the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025; and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra franchise.
The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported Q2 2026 financial results Tuesday July 28, 2026 with ARCALYST (rilonacept, an IL-1α and IL-1β cytokine trap fusion protein) net product revenue of $243.6 million, +55% year-over-year growth. ARCALYST is FDA-approved for the reduction in risk of recurrence of pericarditis in patients 12 years of age and older, and represents Kiniksa's primary commercial franchise. The Q2 revenue trajectory reflects continued cardiovascular-specialist adoption of rilonacept as a maintenance therapy alternative to colchicine-plus-corticosteroid regimens in the recurrent pericarditis population. Kiniksa separately reported Phase 2 data from the KPL-387 program (an investigational IL-1 receptor antagonist monoclonal antibody) showing rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous injection administered once monthly. The company hosted a conference call and webcast at 8:30 AM Eastern Time Tuesday July 28 to discuss Q2 financial performance and portfolio pipeline advancement including KPL-387 next-step development, ARCALYST commercial expansion, and additional pipeline candidates. Kiniksa Pharmaceuticals is one of the peptide-adjacent biotech companies focused on IL-1 pathway inhibition through both antibody and fusion-protein modalities.
BioPharma Dive published post-PCAC editorial coverage Monday July 27, 2026 framing the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session outcome as advisory endorsement of broader use of six of seven peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) despite the panel's rejection of substantive human efficacy or safety evidence. The editorial frames the vote as a substantive break with the FDA's traditional science-based standard for compounding-substance eligibility and highlights the substantive shift in venture capital and pharmaceutical industry positioning that has followed. Capital is now flowing toward peptide-adjacent companies with documented FDA regulatory engagement (formal drug-development programs seeking NDA or BLA approval), well-defined clinical development strategies (Phase 1-3 registrational programs), and scalable manufacturing infrastructure (state-licensed compounding pharmacies with quality-control documentation, or FDA-registered 503B outsourcing facilities). The commentary contrasts this trajectory with the compounding-pharmacy gray market that has historically dominated peptide distribution (research-chemical suppliers, offshore pharmacies, and clinics operating outside FDA oversight). BioPharma Dive's framing anchors on the July 23-24 PCAC vote as the trigger for the current investment-cycle inflection, and notes that Merck's July 16, 2026 FDA approval of LIPFENDRA (enlicitide, macrocyclic peptide PCSK9 inhibitor) validates the legitimate-drug-development pathway that peptide-industry commentary has framed as an alternative to the compounding-first commercial strategy.
Post-PCAC analyst coverage of Hims & Hers Health (NYSE: HIMS) split on the July 23-24 Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 outcome. BofA Securities raised its price target to $36 on the peptide-compounding opportunity, and Canaccord Genuity raised to $40, both citing the July 23-24 PCAC vote and the Hims & Hers acquired California peptide manufacturing facility. Analysts estimate the four Day-1 recommended peptides (BPC-157, KPV, TB-500, MOTS-c) could generate approximately $440 million in Hims & Hers sales by 2027 if the FDA follows through with 503A rulemaking. Truist Securities held at $23 citing the 6-18 month FDA rulemaking timeline and continued uninsured-patient exposure. Barclays sits at $39 (Novo Nordisk partnership thesis). The peptide catalyst lift is tempered by the advisory-vote nature of the PCAC outcome: compounding pharmacies still cannot legally prepare BPC-157, KPV, TB-500, MOTS-c, Semax, or Epitalon under Section 503A today because none of the six substances are on the 503A Bulks List. FDA rulemaking to add each substance takes 6-18 months from the date the agency decides to act. Hims shares closed near $28.50 last week after briefly rallying above $35 on the initial vote outcome.
Bloomberg Businessweek published a long-form feature this week titled 'Peptides Fuel a Multibillion-Dollar Startup Race' covering the peptide industry's post-PCAC-vote investor landscape. The story frames the July 23-24 PCAC recommendation of 6 of 7 peptides for the Section 503A Bulks List as the trigger for a legalization gold rush and profiles the compounding-pharmacy, telehealth, manufacturing, and startup ecosystem positioning to capture what analysts describe as the multibillion-dollar non-GLP-1 peptide market. The feature draws on the analyst framing established earlier in 2026 (Jonah Lupton's projection that Hims & Hers could generate $10-19 billion in annual peptide-related revenue by 2030 if the company captures 4-5% of combined GLP-1 and non-GLP-1 peptide markets) and profiles the venture-capital financing wave, including the General Bio $7.4 million seed round for oral peptide platform work (Axios Pro exclusive July 20), the MindRank $52 million Series B for AI-driven peptide discovery (July 10 digest coverage), and the Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide (July 19-20 digest coverage). The Bloomberg piece anchors the investment thesis on the 6-of-7 PCAC recommendation while noting that FDA rulemaking to actually add BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the 503A list takes 6-18 months per substance from the date the agency decides to act.
Novo Nordisk announced Friday July 24, 2026 that it has filed for a temporary restraining order (TRO) and preliminary injunction in the US District Court for the District of New Jersey to immediately block Eli Lilly's national Zepbound (tirzepatide) and Mounjaro (tirzepatide) direct-to-consumer advertising campaigns. The escalation comes three business days after Novo's original complaint filed Tuesday July 21 alleging that Lilly's ads rely on outdated Wegovy (semaglutide) dose comparisons that do not account for the newer, higher-dose FDA-approved semaglutide options currently available. Through the TRO and preliminary injunction motions, Novo Nordisk seeks immediate court-ordered removal of the disputed Lilly campaigns pending a full merits ruling on the underlying deceptive-advertising claims. Novo also seeks a permanent injunction requiring Lilly to pull all misleading comparative advertising across platforms and to conduct a corrective advertising campaign. The GLP-1 ad war has moved from network TV pharmacy-facing PBM negotiation into full federal court litigation for the first time in the class's US commercialization history. Court hearing dates on the TRO/preliminary injunction have not yet been reported publicly.
Merck (MSD) announced Friday July 24, 2026 seven voluntary, royalty-free, non-exclusive licensing agreements with generic drug manufacturers covering the investigational once-monthly oral HIV prevention pill MK-8527 (alimatravir). The licensees are Aspen Pharmacare (South Africa), Quality Chemical Industries (Uganda), and UCL Kenya in sub-Saharan Africa, plus Aurobindo, Cipla, Emcure, and Viatris in India. The territorial scope covers 129 low- and middle-income countries including every African nation. Alimatravir is an investigational late-stage once-monthly long-acting oral medicine for HIV-1 prevention, currently in Phase 3 development. Phase 3 topline results are not expected until late 2027. Alimatravir is designed to provide one month of protection from HIV-1 starting within one hour after dosing. Coverage frames the licensing structure as one of the broadest generic-access pre-approval commitments Merck has undertaken for an HIV asset. The announcement follows the April 7 STAT reporting that Merck's experimental HIV prevention pill could be made for less than $5 a year at manufacturing cost. Merck plans to file for regulatory approval in 2027-2028 with market launch dependent on Phase 3 outcome.
Hims & Hers Health (NYSE: HIMS) shares surged 10-13% intraday on Thursday July 23, 2026 following the FDA Pharmacy Compounding Advisory Committee (PCAC) 8-6 votes in favor of adding BPC-157 and KPV to the Section 503A Bulks List. The stock reaction reflected investor recognition that Hims & Hers is one of the largest telehealth commercial channels positioned to sell legally compounded peptides through licensed 503A pharmacies if the FDA follows the advisory recommendation and completes rulemaking. Hims Chief Medical Officer Dr. Anant Vinjamoori's public-comment testimony was reportedly influential in the panel outcome. Vinjamoori shared the anecdote that a colleague had recently sent him a photograph of a bodega in Queens selling peptides, then argued: 'A no vote would not end those distribution channels or use. It would instead move it deeper into a market with no production or sourcing standards, no physician, no monitoring, and no record.' Vinjamoori also acknowledged the 'relatively sparse clinical evidence for these peptides' before making the harm-reduction argument. Hims stands to benefit commercially: the company has built peptide capabilities including a California manufacturing facility acquired in 2025.
Time Magazine published a same-day analysis Thursday July 23, 2026 headlined 'An FDA Committee Just Voted in Favor of Peptides, Despite the Agency's Opposition,' framing the 8-6 votes on BPC-157 and KPV as an unusual advisory-panel override of the FDA career-staff position. The Time analysis notes that before the meeting, more than a half-dozen new PCAC members were added to the panel with documented ties to the peptide industry (physicians, pharmacists, and consultants who work with the substances commercially), a composition change first reported by STAT News on June 29 that has been central to the pre-vote debate. Washington Times ran a parallel same-day feature headlined 'FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers,' framing BPC-157 through its influencer-endorsement pathway. ABC News, NPR (nationally syndicated across ~40 public media outlets), the Associated Press, and Time together produced the mainstream media response that PCAC-vote days typically generate for major regulatory decisions. The FDA is expected to review the recommendation and initiate rulemaking; the timeline for actual 503A bulks-list addition is 6-18 months.
Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).
NPR published a nationally syndicated feature Wednesday July 22, 2026 titled 'FDA panel to consider easing restrictions on peptide production,' extending the mainstream-media wave into the eve of the July 23-24 PCAC vote. The feature is NPR's second major peptide policy piece in two weeks, following the July 8 nationally syndicated 'What's behind the push to make peptide therapies more readily available.' The pre-vote mainstream media cycle now includes the July 8 NPR feature, the July 9 Washington Post Health Brief 'The peptide showdown' by Megan R. Wilson, the July 17 Washington Post FDA conflict-of-interest report, the July 21 Forbes op-ed by Dr. Omer Awan ('FDA's Review of Peptides Signals a Growing Public Health Challenge — Separating Science from Hype'), and the July 22 NBC News explainer 'What to know about the seven peptides an FDA advisory panel is set to review this week.' Regional NPR affiliates and public media stations (WFAE Charlotte, Wyoming Public Media, WVAS FM, WJCT Jacksonville, and KPBS San Diego) picked up the syndication under the alternate title 'Peptides get their regulatory closeup.' The coverage volume signals that the story has moved past the trade press (Endpoints, STAT, FiercePharma) and into general-audience awareness heading into the two-day vote.
Samsung Bioepis and Korean biotech IntoCell announced Wednesday July 22, 2026 that they have entered into a commercial license agreement for SBE303, one of the antibody-drug conjugate (ADC) candidates the two companies are jointly developing. SBE303 is a next-generation ADC cancer treatment targeting the Nectin-4 protein, combining Samsung Bioepis's proprietary humanized antibody with IntoCell's linker platform and a payload originally developed by IntoCell under patent license from China's Frontline. Samsung Bioepis is currently conducting a global Phase 1 clinical trial of SBE303 in the United States and Korea, with plans to evaluate safety and preliminary efficacy in 149 patients with advanced refractory solid tumors through July 2030. The deal extends Samsung Bioepis's strategic shift from a biosimilar manufacturer to a novel-drug developer, and adds to the July 2026 payload-and-conjugate consolidation wave alongside Novartis's July 6 $1.5 billion Myricx Bio acquisition (NMTi payload platform), Lonza's July 2 Nona Biosciences TfR1 blood-brain-barrier deal, SOTIO's July 14 FDA Fast Track Designation for SOT109 (CDH17 ADC), and Simris Group's July 16 appointment of former Heidelberg Pharma CEO Andreas Pahl to lead its cyanobacterial microcystin ADC payload platform.
Lonza (SIX: LONN) reported first-half 2026 earnings Wednesday July 22, 2026: sales of CHF 3.37 billion (up 11.2% at actual exchange rate, up 16.0% at constant exchange rate), CHF 595 million profit (CHF 8.18 per share) versus CHF 426 million (CHF 5.68 per share) in H1 2025, and CHF 1.2 billion core EBITDA (up 27.4% year-over-year) at a 34.8% margin (up 4.4 percentage points). The Advanced Synthesis division, which houses small-molecule and bioconjugate manufacturing, delivered 27.7% CER sales growth driven by demand for small-molecule and bioconjugate products; the Integrated Biologics division grew 10% CER. Lonza lifted its full-year 2026 margin outlook and confirmed CDMO capacity expansion in Stein, Switzerland following a major-pharma ADC clinical and commercial manufacturing agreement. The Lonza H1 print, combined with the July 20 Samsung Biologics $1.8 billion PolyPeptide tender offer and the July 2 Lonza-Nona Biosciences TfR1 BBB deal, sustains the peptide- and biologic-CDMO consolidation thesis that has run through the first half of 2026. Peptide-based GLP-1 manufacturing capacity constraints continue to drive premium CDMO pricing.